Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2025-05-21 Notice of Dividend Amou…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2024年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2024 annual equity distribution (dividend) plan of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the dividend amount, payment method, tax treatment, record date, and ex-dividend date. The document is short (1230 characters) and focuses on dividend distribution specifics rather than financial results or comprehensive reports. It explicitly states the dividend per share and payment dates, which aligns with a Notice of Dividend Amount filing. There is no indication of it being a full annual report, earnings release, or other report types. Therefore, the document fits the definition of a Notice of Dividend Amount (DIV).
2025-05-21 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司二级子公司增资暨关联交易的核查意见
Regulatory Filings
2025-05-19 Chinese
关于二级子公司增资暨关联交易公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a capital increase in a secondary subsidiary and related party transaction. It details the transaction parties, shareholding changes, approval procedures, pricing policy, and impact on the company. It is a regulatory disclosure about a financing event involving a related party, not a full financial report or earnings release. The document length is about 3,000 characters, which is typical for a detailed announcement but not a full report. The content focuses on capital increase and related party transaction details, fitting the Capital/Financing Update category rather than Annual Report, Interim Report, or Regulatory Filings. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-05-19 Chinese
北京德恒（杭州）律师事务所关于江西新赣江药业股份有限公司2024年年度股东会的法律意见书
Regulatory Filings
2025-05-18 Chinese
关于参加江西辖区上市公司2025年投资者网上集体接待日说明会预告公告
Investor Presentation Classification · 90% confidence The document is a short announcement (923 characters) about a scheduled investor online meeting hosted by the company and local associations. It includes details about the meeting time, platform, participants, and topics to be discussed such as 2024 annual performance and governance. There is no actual financial data or report content included. The document serves as a notice or invitation for an investor presentation event rather than the presentation or report itself. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, albeit in announcement form. The length and content do not match a full Annual Report or Earnings Release, nor is it a regulatory filing or certification. Hence, the classification is IP with high confidence.
2025-05-18 Chinese
2024年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2024 Annual General Meeting (AGM) resolution announcement for Jiangxi New Ganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on various proposals including the 2024 financial reports, profit distribution plan, and remuneration schemes for 2025. The document includes voting percentages and legal compliance statements from lawyers. It is a formal announcement of the AGM resolutions and voting outcomes rather than the full AGM materials or presentations. The document length is about 3094 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-18 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.